Please assess the completion status of the following clinical trial:

Trial Title: Regional Prophylactic Vancomycin in Revision Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Revision total knee arthroplasty~* Informed consent given~Exclusion Criteria:~* Current treatment with IV Vancomycin within the preceding 7 days~* Previous hypersensitivity to vancomycin~* Significant cardiac or respiratory abnormality~* Contraindications to using the intraosseous vascular access system (EZ-IO)~* Sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin 500mg intraosseous (Type: EXPERIMENTAL): Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
- Vancomycin 1g IV (Type: ACTIVE_COMPARATOR): Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.

Based on this trial design, predict the completion outcome and termination type (if applicable).